22 May 2013
Keywords: proximagen, narrows, fiscal, loss, neuroscience, uk, drug
Article | 30 March 2009
Proximagen Neuroscience, a UK drug discovery and development company focused on neurodegenerative diseases, has narrowed its loss for the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 March 2009
31 March 2009
21 May 2013
© 2013 thepharmaletter.com